Indication: Non-Small Cell Lung Cancer (NSCLC)

A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

Metastatic PD-L1+NSCLC

Sub-indication: NSCLC PD-L1+

Line of Therapy: 1st line metastatic, HLA A2+

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: BrightPath Biotherapeutics

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.